8-K: Henry Schein Completes $250 Million Strategic Investment by KKR, Appoints New Board Member

Henry Schein finalizes a $250 million private placement of common stock to KKR and appoints William K. Dan Daniel to its Board of Directors.

Summary

• Henry Schein, Inc. completed a $250 million strategic investment from KKR on May 16, 2025.
• The company issued 3,285,152 shares of common stock to KKR at a price of approximately $76.10 per share.
• KKR now holds approximately 12% of Henry Schein's common shares.
• William K. Dan Daniel, an Executive Advisor at KKR, has been appointed to Henry Schein's Board of Directors as an independent director.
• The company and KKR entered into a Registration Rights Agreement providing KKR with certain customary registration rights.
• The size of the Board was increased to 16 directors to accommodate the new appointment.
• Mr. Daniel has been appointed to the Boards Compensation Committee and to the Boards Strategic Advisory Committee.
• Max Lin, Partner at KKR, became a member of Henry Schein's Board of Directors on May 2, 2025.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the successful completion of a significant investment and the addition of experienced board members. This suggests confidence in the company's future prospects.

Positives

• The $250 million investment strengthens Henry Schein's financial position.
• The addition of William K. Dan Daniel to the Board brings extensive experience in the healthcare sector.
• KKR's investment validates Henry Schein's business strategy and growth potential.
• The appointment of Max Lin to the Board of Directors brings additional healthcare expertise.

Future Outlook

Henry Schein aims to continue executing its BOLD+1 strategy and creating long-term value for stakeholders with the support of KKR's investment and the expertise of the new board members.

Management Comments

• Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein, stated that the deep experience in health care, operations, and strategic growth of the new board members will be invaluable as the company continues executing on its BOLD+1 strategy.

Industry Context

This investment reflects the ongoing trend of private equity firms investing in healthcare companies, particularly those providing solutions to dental and medical practitioners. KKR's expertise in the healthcare sector positions Henry Schein to potentially benefit from strategic guidance and operational improvements.

Comparison to Industry Standards

• KKR's investment in Henry Schein is similar to other private equity investments in the healthcare distribution and solutions space, such as Blackstone's investment in TeamHealth and Carlyle Group's investment in Medline Industries.
• The 12% stake acquired by KKR is a significant minority position, allowing them to influence strategic decisions while Henry Schein maintains operational control.
• The appointment of KKR executives to the board is a common practice in private equity investments, ensuring alignment of interests and active participation in the company's strategic direction.

Management Changes

Stakeholder Impact

• Shareholders will likely view the investment positively, potentially leading to an increase in stock value.
• Employees may benefit from the company's strengthened financial position and strategic direction.
• Customers may see improved solutions and services as a result of the investment and strategic guidance.
• Suppliers could experience increased business opportunities due to Henry Schein's growth.

Key Dates

Keywords

Henry Schein, KKR, Strategic Investment, Board of Directors, Private Placement, Common Stock, Healthcare Solutions